Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
1 clinical trials · Condition
◉ Watch Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
| Record | Firm | Date |
|---|---|---|
| HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia (NCT07137637) | Hangzhou Polymed Biopharmaceuticals, Inc. | 2026-04-10 |
Track Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) automatically
Every clearance here is in the API, with alerts when new ones post.